Fixed combinations of topical glaucoma medications

Current Opinion in Ophthalmology

Volumn 15, Issue 2, 2004, Pages 132-135

  Fechtner, Robert D ^a   Realini, Tony ^b  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Clinical management; Fixed combination therapy; Glaucoma; Glaucoma medical therapy; Intraocular pressure

Indexed keywords

ADRENALINE PLUS PILOCARPINE; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL PLUS PILOCARPINE; BIMATOPROST PLUS TIMOLOL; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; PILOCARPINE PLUS TIMOLOL; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TIMOLOL PLUS TRAVOPROST; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FIXED COMBINATION THERAPY; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OPHTHALMIC SOLUTIONS;

EID: 1842608679     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200404000-00013     Document Type: Review

References (25)

1. Kobelt-Nguyen G, Gerdtham UG, Alm A: Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 1998, 7:95-104.
2. Kass MA, Heuer DK, Higginbotham EJ, et al.: The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002, 120:701-713. The Ocular Hypertension Treatment Study demonstrated that IOP reduction prevented glaucoma and identified baseline risk factors for developing glaucoma. Based on its findings, patients at higher risk can be identified and treated before glaucoma vision loss ensues.
3. Chrai SS, Makoid MC, Eriksen SP, et al.: Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974, 63:333-338.
4. Lavin MJ, Wormald RP, Migdal CS, et al.: The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990, 108:1543-1548.
5. Broadway DC, Grierson I, O'Brien C, et al.: Adverse effects of topical anti-glaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 1994, 112:1446-1454.
6. Clineschmidt CM, Williams RD, Snyder E, et al.: A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology 1998, 105:1952-1959.
7. Boyle JE, Ghosh K, Gieser DK, et al.: A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology 1998, 105:1945-1951.
8. Strohmaier K, Snyder E, Dubiner H, et al.: The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology 1998, 105:1936-1944.
9. Choudhri S, Wand M, Shields MB: A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol 2000, 130:832-833.
10. Gugleta K, Orgul S, Flammer J: Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices. Curr Med Res Opin 2003, 19:330-335.
11. Bacharach J, Delgado MF, Iwach AG. Comparison of the efficacy of the fixed-combination timolol/dorzolamide versus concomitant administration of timolol and dorzolamide. J Ocul Pharmacol Ther 2003, 19:93-96. One of a trio of published reports [9,10] demonstrating a clinically significant reduction in IOP when switching from concomitant timolol and dorzolamide to the dorzolamide-timolol fixed combinations.
12. Honrubia FM, Larsson LI, Spiegel D: A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma. Acta Ophthalmol Scand 2002, 80:635-641. This trial randomized 226 patients uncontrolled on timolol monotherapy to either latanoprost or dorzolamide-timolol fixed combination and found similar efficacy. Differences other than efficacy should determine selection from among these choices.
13. Konstas AG, Papapanos P, Tersis I, et al.: Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 2003, 110:1357-1360.
14. Orzalesi N, Rossetti I, Bottoli A, et al.: Comparison of latanoprost, brimonidine and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand Suppl 2002, 236:55.
15. Day DG, Schacknow PN, Wand M, et al.: Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2003, 135:138-143.
16. Sall KN, Greff LJ, Johnson-Pratt LR, et al.: Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003, 110:615-624.
17. Zabriskie N, Netland PA: Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials. Adv Ther 2003, 20:92-100.
18. Bucci MG: Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma 1999, 8:24-30.
19. Konstas AG, Nakos E, Tersis I, et al.: A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol 2002, 133:753-757. This crossover study of 36 patients demonstrated that concomitant use of latanoprost and timolol lowers IOP better when dosed at night rather than in the morning.
20. Higginbotham EJ, Feldman R, Stiles M, et al.: Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol 2002, 120:915-922. This large, 6-month, randomized, multicenter clinical trial of more than 400 patients demonstrated a modest 1-mmHg advantage to using the latanoprost-timolol fixed combination over latanoprost monotherapy.
21. Pfeiffer N: A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002, 240:893-899.
22. Larsson LI: Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension. J Glaucoma 2001, 10:109-114.
23. Stewart WC, Stewart JA, Day D, et al.: Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand 2003, 81:242-246.
24. O'Connor DJ, Martone JF, Mead A: Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002, 133:836-837. Although small and retrospective, this analysis demonstrated that dorzolamide lowered IOP more than β-blockers or brimonidine when added to latanoprost. As prostaglandins become mainstream first-line agents, additivity studies such as this will guide future adjunctive therapy choices.
25. Realini T, Fechtner RD: 56,000 ways to treat glaucoma. Ophthalmology 2002, 109:1955-1956.